Bone Metastases
Conditions
Keywords
bone localisations of haematological diseases, Cancer, bone metastasis, haematological diseases, quality of life, epidemiological data
Brief summary
Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap. Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures. To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient
Interventions
None listed
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 or over, * Patient whose file is presented to the OOSLOH MM and who has not objected to the use of his non-nominative clinical, biological and imaging data * Social insured patient
Exclusion criteria
* Patient who died before presentation to OOSLOH MM, * Minor patient, * Patient objecting to the use of their data for research purposes, * Patient unable to express his right to object to his participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of alive patients | through study completion, an average of 10 years |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients without bone disease recurrence | within one year after the multidisciplinary meeting |
| Time to bone disease recurrence | through study completion, an average of 10 years |
| Number of bone recurrence Number of bone recurrence | At each presentation of the patient file's to the MM,on average every week |
| Epidemiological datas | At the first presentation of patient's file to the MM, on average every week |
Contacts
PRINCIPAL_INVESTIGATORMarie-Hélène VIEILLARD, MD
University Hospital, Lille
Outcome results
None listed